Anti Varicella Zoster Antibody Positivity C5936840
Indicates the presence of antibodies against the varicella zoster virus, meaning past infection or vaccination. This shows immunity to chickenpox. No treatment is needed.
Key facts at a glance
- ICD-10
- B99.9
- ICD-11
- 1A00.0
- Body system
- infectious
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Ophthalmic zoster
Fever or malaise
(infectious)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Varicella rash
(infectious)Fever
(infectious)Malaise
(infectious)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antimicrobial or antiviral therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Immunity status documentation
Document positive antibody status in medical records to confirm varicella immunity for healthcare and employment purposes.
Immune support optimization
Lifestyle and nutritional support to maintain healthy immune function, potentially reducing risk of viral reactivation.
Additional treatment options
Antiviral therapy if reactivation occurs
Antiviral medications such as acyclovir, valacyclovir, or famciclovir if the latent virus reactivates as shingles, reducing severity and duration.
medicationShingrix vaccination counseling
Discuss recombinant zoster vaccine for patients over 50 or immunocompromised to prevent herpes zoster reactivation despite antibody positivity.
procedureStress reduction and sleep hygiene
Stress management techniques and adequate sleep to support immune system function and reduce viral reactivation triggers.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Varicella Zoster Antibody Positivity C5936840?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Centers for Disease Control and Prevention. Prevention of varicella and herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2022.
Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015.
Lafayette PM, Arantes NA, Gouvea PS, et al. Immunogenicity and safety of recombinant herpes zoster vaccine in seropositive individuals. Vaccine. 2021.
Li S, Liu Y, Wang Q, et al. Persistence of varicella-zoster virus antibodies after vaccination: a systematic review and meta-analysis. J Infect Dis. 2020.
Medication Comparisons
Compare medications used to treat Anti Varicella Zoster Antibody Positivity C5936840. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy